164 related articles for article (PubMed ID: 33076510)
1. Simple Method to Measure the Aerodynamic Size Distribution of Porous Particles Generated on Lyophilizate for Dry Powder Inhalation.
Miyamoto K; Taga H; Akita T; Yamashita C
Pharmaceutics; 2020 Oct; 12(10):. PubMed ID: 33076510
[TBL] [Abstract][Full Text] [Related]
2. Optimization of Very Low-Dose Formulation of Vitamin D3 with Lyophilizate for Dry Powder Inhalation System by Simple Method Based on Time-of-Flight Theory.
Miyamoto K; Yanagisawa M; Taga H; Yamaji H; Akita T; Yamashita C
Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33946783
[TBL] [Abstract][Full Text] [Related]
3. Humidity-induced changes of the aerodynamic properties of dry powder aerosol formulations containing different carriers.
Zeng XM; MacRitchie HB; Marriott C; Martin GP
Int J Pharm; 2007 Mar; 333(1-2):45-55. PubMed ID: 17064863
[TBL] [Abstract][Full Text] [Related]
4. Novel dry powder inhalation system based on dispersion of lyophilisates.
Claus S; Schoenbrodt T; Weiler C; Friess W
Eur J Pharm Sci; 2011 May; 43(1-2):32-40. PubMed ID: 21440061
[TBL] [Abstract][Full Text] [Related]
5. Air permeability of powder: a potential tool for Dry Powder Inhaler formulation development.
Le VN; Robins E; Flament MP
Eur J Pharm Biopharm; 2010 Nov; 76(3):464-9. PubMed ID: 20854906
[TBL] [Abstract][Full Text] [Related]
6. Radiolabeling Method for Lyophilizate for Dry Powder Inhalation Formulations.
Miyamoto K; Akita T; Yamashita C
Pharmaceutics; 2022 Mar; 14(4):. PubMed ID: 35456593
[TBL] [Abstract][Full Text] [Related]
7. The effect of dose on the characterization of aerodynamic particle-size distributions of beclomethasone dipropionate metered-dose inhalers.
el-Araud KA; Clark BJ; Kaahwa C; Anum P; Chrystyn H
J Pharm Pharmacol; 1998 Oct; 50(10):1081-5. PubMed ID: 9821652
[TBL] [Abstract][Full Text] [Related]
8. Aerodynamic particle size analysis of aerosols from pressurized metered-dose inhalers: comparison of Andersen 8-stage cascade impactor, next generation pharmaceutical impactor, and model 3321 Aerodynamic Particle Sizer aerosol spectrometer.
Mitchell JP; Nagel MW; Wiersema KJ; Doyle CC
AAPS PharmSciTech; 2003 Oct; 4(4):E54. PubMed ID: 15198549
[TBL] [Abstract][Full Text] [Related]
9. Particle characteristics and lung deposition patterns in a human airway replica of a dry powder formulation of polylactic acid produced using supercritical fluid technology.
Cheng YS; Yazzie D; Gao J; Muggli D; Etter J; Rosenthal GJ
J Aerosol Med; 2003; 16(1):65-73. PubMed ID: 12737686
[TBL] [Abstract][Full Text] [Related]
10. Development of a laser diffraction method for the determination of the particle size of aerosolised powder formulations.
Marriott C; MacRitchie HB; Zeng XM; Martin GP
Int J Pharm; 2006 Dec; 326(1-2):39-49. PubMed ID: 16942848
[TBL] [Abstract][Full Text] [Related]
11. Differences in estimates of size distribution of beryllium powder materials using phase contrast microscopy, scanning electron microscopy, and liquid suspension counter techniques.
Stefaniak AB; Hoover MD; Dickerson RM; Day GA; Breysse PN; Scripsick RC
Part Fibre Toxicol; 2007 Feb; 4():3. PubMed ID: 17328812
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of a new Aerodynamic Particle Sizer Spectrometer for size distribution measurements of solution metered dose inhalers.
Stein SW; Myrdal PB; Gabrio BJ; Obereit D; Beck TJ
J Aerosol Med; 2003; 16(2):107-19. PubMed ID: 12823905
[TBL] [Abstract][Full Text] [Related]
13. The influence of physical properties and morphology of crystallised lactose on delivery of salbutamol sulphate from dry powder inhalers.
Kaialy W; Martin GP; Larhrib H; Ticehurst MD; Kolosionek E; Nokhodchi A
Colloids Surf B Biointerfaces; 2012 Jan; 89():29-39. PubMed ID: 21962946
[TBL] [Abstract][Full Text] [Related]
14. Formulation and comparison of spray dried non-porous and large porous particles containing meloxicam for pulmonary drug delivery.
Chvatal A; Ambrus R; Party P; Katona G; Jójárt-Laczkovich O; Szabó-Révész P; Fattal E; Tsapis N
Int J Pharm; 2019 Mar; 559():68-75. PubMed ID: 30677482
[TBL] [Abstract][Full Text] [Related]
15. Determination of Passive Dry Powder Inhaler Aerodynamic Particle Size Distribution by Multi-Stage Cascade Impactor: International Pharmaceutical Aerosol Consortium on Regulation & Science (IPAC-RS) Recommendations to Support Both Product Quality Control and Clinical Programs.
Mitchell JP; Stein SW; Doub W; Goodey AP; Christopher JD; Patel RB; Tougas TP; Lyapustina S
AAPS PharmSciTech; 2019 May; 20(5):206. PubMed ID: 31147791
[TBL] [Abstract][Full Text] [Related]
16. The role of lactose carrier on the powder behavior and aerodynamic performance of bosentan microparticles for dry powder inhalation.
Lee HJ; Lee HG; Kwon YB; Kim JY; Rhee YS; Chon J; Park ES; Kim DW; Park CW
Eur J Pharm Sci; 2018 May; 117():279-289. PubMed ID: 29510172
[TBL] [Abstract][Full Text] [Related]
17. Investigation of potential substandard dry powder inhalers on EU and North African markets - evaluation of the delivered and fine particle doses.
Zhang Y; Hubert P; Hubert C
J Drug Assess; 2022; 11(1):20-25. PubMed ID: 36213210
[TBL] [Abstract][Full Text] [Related]
18. Time-of-flight aerodynamic particle size analyzers: their use and limitations for the evaluation of medical aerosols.
Mitchell JP; Nagel MW
J Aerosol Med; 1999; 12(4):217-40. PubMed ID: 10724637
[TBL] [Abstract][Full Text] [Related]
19. Dry-powder inhalers: evaluation of testing methodology and effect of inhaler design.
Broadhead J; Rouan SK; Rhodes CT
Pharm Acta Helv; 1995 Jul; 70(2):125-31. PubMed ID: 7651970
[TBL] [Abstract][Full Text] [Related]
20. Dry powders for oral inhalation free of lactose carrier particles.
Healy AM; Amaro MI; Paluch KJ; Tajber L
Adv Drug Deliv Rev; 2014 Aug; 75():32-52. PubMed ID: 24735676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
